Private Wealth Management Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Private Wealth Management Group’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-62	Closed	-$1.95K	–	1513
2026 Q2	$1.95K	Hold	62	–	–	﹤0.01%	1172
2026 Q1	$1.54K	Buy	62 +6	+11%	+$143	﹤0.01%	1158
2025 Q4	$1.31K	Sell	56 -3	-5%	-$67	﹤0.01%	1198
2025 Q3	$1.16K	Sell	59 -21	-26%	-$432	﹤0.01%	1247
2025 Q2	$1.74K	Buy	80 +31	+63%	+$732	﹤0.01%	1126
2025 Q1	$1.19K	Sell	49 -4	-8%	-$90	﹤0.01%	1214
2024 Q4	$1.11K	Buy	+53	New	+$1.14K	﹤0.01%	1270

Other funds holding CPRX

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Private Wealth Management Group's CPRX Position: Q3 2026 in Review

Private Wealth Management Group sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 62 shares — an estimated $1.95K sold.

Private Wealth Management Group first reported a position in CPRX in Q4 2024 and held it in 7 quarters. The position peaked at $1.95K in Q2 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

Private Wealth Management Group reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
Private Wealth Management Group sold 62 Catalyst Pharmaceutical shares in Q3 2026, an estimated $1.95K.
Private Wealth Management Group first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 7 quarters.
Private Wealth Management Group's Catalyst Pharmaceutical position peaked at $1.95K in Q2 2026.
2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Private Wealth Management Group's 13F filing for Q3 2026, filed 19 Oct 2026.